| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tetracaine HCl Basic Information:
Pharmaceutical Anesthetic Purity HCl Powder CAS 136-47-0 Tetracaine Lidocaine
Lidocaine hydrochloride undergoes rapid metabolism in the liver, with both unchanged drug and its metabolites being excreted by the kidneys. This biotransformation encompasses oxidative N-dealkylation, ring hydroxylation, amide linkage cleavage, and conjugation. The major biotransformation pathway, N-dealkylation, produces monoethylglycinexylidide and glycinexylidide metabolites, which exhibit pharmacological and toxicological actions similar to but less potent than those of Lidocaine hydrochloride. About 90% of administered Lidocaine hydrochloride is excreted as various metabolites, with less than 10% excreted unchanged. The predominant metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline.
Lidocaine HCl is a potent amide local anesthetic, revered for its efficacy and reliability in medical applications.
As the dosage increases, both therapeutic effects and toxicity levels rise; at sub-toxic plasma concentrations, Lidocaine HCl exhibits notable anti-convulsive properties.
Blood concentrations exceeding 5μg/ml can induce convulsions.
){kind=link}